Phase 1 N=9 Tobacco Tactics Website for Veteran Smokers
Smoking
Primary: Self Reported 30 Day Smoking Quit Rate — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers
Healthy Subjects
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 4; 2; 4; 3 Participants
Phase 1 N=18 Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
Healthy
Primary: Empagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss) — 4580.38; 4621.37 nmol*h/L
Phase 1 N=6 A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
Refractory Solid Tumors in Children
Primary: Dose Limiting Toxicity — 2 participants
Phase 1 N=23 Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Healthy
Primary: Total Empa: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss) — 5850; 5680 nmol*h/L
Phase 1 N=15 Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Participants Experiencing a Dose-limiting Toxicity (DLT) — 2; 1 Participants
Phase 1 N=17 BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Neoplasms
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) During 1st Course — 0; 3; 0; 1 participants
Phase 1 N=12 Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Prostate Cancer
Primary: Number of Patients Experiencing Dose Limiting Toxicities (DLT's) — 1; 2 participants
Phase 1 N=25 Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
Glaucoma · Ocular Hypertension
Primary: Maximum Observed Travoprost Free Acid Plasma Concentration (Cmax) — 0.0256; 0.0471; 0.0258; 0.0109 ng/mL
Phase 1 N=21 A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Change in Brachial Artery Diameter — -0.93 percentage of dilation
Phase 1 N=127 Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Inflammatory Bowel Disease
Primary: Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74 — 88.5; 90.3 percentage of participants
Phase 1 N=171 Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Endpoint is the Occurrence of Dose Limiting Toxicity (DLT). — 0; 0 participants
Phase 1 N=10 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Neuromyelitis Optica
Primary: Number of Adverse Safety Events During Hospitalization — 0 adverse safety events
Phase 1 N=28 A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 85020; 90030; 16220; 16120 (nanogram*hour) per milliliter (ng*h/mL)
Phase 1 N=26 Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
Diabetes Mellitus
Primary: Time to Maximum Serum Insulin Concentration (Tmax) — 97.5; 48.0; 163; 67.8 Minutes — p=0.0006